EBITDA: Income before interest, taxes, depreciation and amortization.
Moleculin Biotech, Inc. (MBRX) had EBITDA of $-5.69M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-7.64M |
|
-- |
|
-- |
|
$5.72M |
|
$-5.72M |
|
$-1.92M |
|
$-7.64M |
|
$-7.64M |
|
$-7.64M |
|
$-7.64M |
|
$-7.64M |
|
$-7.64M |
|
$-5.72M |
|
|
EBITDA |
$-5.69M |
15.53M |
|
15.53M |
|
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$9.08M |
|
$0.10M |
|
$12.52M |
|
$21.59M |
|
$7.91M |
|
-- |
|
$20.84M |
|
$28.76M |
|
$-7.17M |
|
$-18.31M |
|
$-7.17M |
|
30.21M |
|
| Cash Flow Statement Financials | |
$-10.15M |
|
-- |
|
$13.42M |
|
$4.28M |
|
$7.56M |
|
$3.28M |
|
$0.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.15M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
106.63% |
|
41.72% |
|
-35.38% |
|
106.63% |
|
$-0.24 |
|
$-0.65 |
|
$-0.65 |
|